PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

Under the Beneaved B	Poduction Act of 1995, no	nereone	U.S. Patent a	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.	
Unider the Paperwork N	Reduction Act of 1995, No	Delsons	Application Number	10/023,969	
TRANSMITTAL FORM  (to be used for all correspondence after initial filing)			Filing Date	December 17, 2001	
			First Named Inventor	John M. Irving, et al.	
		a)	Art Unit	1648	
		<i>"</i>	Examiner Name	Ulrike Winkler	
Total Number of Pages in This Submission		4	Attorney Docket Number	084/002	
		ENCL	OSURES (Check all that a	apply)	
Extension of Time Express Abandon Information Disclo Certified Copy of Document(s) Response to Miss incomplete Applic	hed  y (3 pages)  declaration(s)  Request  ment Request  psure Statement  Priority  sing Parts/		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addres Ferminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Regto Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm or Individual Signature			J. Michael Schiff, Registrat		
Date			February 19, 2003		
		CER	TIFICATE OF HAND DELIV	/ERY	
I hereby certify that this correspondence is being hand delivered to the Commissioner for Patents, Washington, DC 20231 on this date:  February 21, 2003					
Typed or printed Shari Hall White					
Signature	Ana -	1	all white	Date February <u>21,</u> 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF HAND DELIVERY

I hereby certify that this paper is being delivered by hand to the U.S. Patent Office in accordance with 37 CFR § 1.6(b), addressed to the Commissioner for Patents & Trademarks, Washington, D.C. 20231, on the date indicated.

Name

Jehnay 21, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: J. Irving & J. Lebkowski

Filing Date: December 17, 2001

Serial No: 10/023,969

Docket: 084/002

Title: CHIMERIC CYTOLYTIC VIRUSES FOR

**CANCER TREATMENT** 

Art Unit: 1648

Examiner: Ulrike Winkler, Ph.D.

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents and Trademarks Washington, D.C. 20231

Dear Sir,

This paper is responsive to the Restriction Requirement mailed on January 27, 2003 (Paper No. 5), for which a shortened statutory period for reply is set to expire on April 27, 2003.

Accordingly, this paper is timely filed.

Please enter the following remarks.